Glioblastoma (GBM) is the deadliest form of brain cancer, with a median survival of less than
2 years despite surgical resection, radiation, and chemotherapy. GBM's rapid progression …

The emergence of immune checkpoint blockade therapies over the last decade has
transformed cancer treatment in a wide range of tumor types. Unprecedented and durable …

T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on
lymphocytes that was recently propelled under the spotlight as a major emerging target in …

In cancer-immunity cycle, the immune checkpoint PD1 and its ligand PDL1 act as
accomplices to help tumors resist to immunity-induced apoptosis and promote tumor …

ABSTRACT Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell
checkpoint and plays a central role in regulating T cell exhaustion. Binding of PD-1 to its …

Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The
current standard of care involves surgical resection (if possible) followed by concomitant …

NK cells play important roles in innate defenses against viruses and in the control of tumor
growth and metastasis. The regulation/induction of NK cell function is mediated by an array …

T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory receptor expressed
on several types of lymphocytes. Efficacy of antibody blockade of TIGIT in cancer …

Over the past decade, immune checkpoint inhibitors (ICIs) have emerged as a revolutionary
cancer treatment modality, offering long-lasting responses and survival benefits for a …

As a promising alternative platform for cellular immunotherapy, natural killer cells (NK) have
recently gained attention as an important type of innate immune regulatory cell. NK cells can …